1621P First-line pembrolizumab alone or with investigational agents for advanced melanoma: Updated results from the phase I/II KEYMAKER-U02 substudy 02B.
Saved in:
| Title: | 1621P First-line pembrolizumab alone or with investigational agents for advanced melanoma: Updated results from the phase I/II KEYMAKER-U02 substudy 02B. |
|---|---|
| Authors: | Gogas, H.1 (AUTHOR), Dummer, R.2 (AUTHOR), Shapira-Frommer, R.3 (AUTHOR), Pigozzo, J.4 (AUTHOR), Ascierto, P.A.5 (AUTHOR), Gaudy Marqueste, C.6 (AUTHOR), Portnoy, D.7 (AUTHOR), Del Vecchio, M.8 (AUTHOR), Bar-Sela, G.9 (AUTHOR), Cohen, J.10 (AUTHOR), Di Giacomo, A.M.11 (AUTHOR), Ribas, A.12 (AUTHOR), Dutriaux, C.13 (AUTHOR), Belli, C.14 (AUTHOR), Cohen, G.L.15 (AUTHOR), Dokhan, R.16 (AUTHOR), Jing, N.17 (AUTHOR), Lal, R.18 (AUTHOR), Long, G.V.19 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS962-S963. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.2249 |
